Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when?
      loading

      Chapter

      To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when?

      DOI link for To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when?

      To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when? book

      To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when?

      DOI link for To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when?

      To what extent should genetic studies be incorporated for assessment of venous and arteriovenous malformations, and when? book

      BySandro Michelini, Stefano Paolacci, Matteo Bertelli
      BookVascular Malformations

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 2019
      Imprint CRC Press
      Pages 4
      eBook ISBN 9780367255343
      Share
      Share

      ABSTRACT

      Venous and arteriovenous malformations (VMs and AVMs, respectively) are rare vascular malformations that affect veins and arteriovenous connections, respectively. Both malformations can be diagnosed by clinical and histological examinations. Most of these malformations are sporadic; however, there may be cases of inherited malformations. Genetic testing is important to identify the molecular cause and establish the recurrence risk in families. Genetic testing should also be used because drugs that target specific proteins or pathways may be used for patients with known mutations in order to give more focused treatments. In those kinds of malformations, PI3K/AKT/mTOR and RAS/MAPK pathways are hyperactivated (as in tumors); therefore, inhibitors of those pathways can be found among drugs used in cancer therapies. Patients with VMs and AVMs should always be subject to genetic testing for the identification of the molecular cause (associated gene, somatic or germline mutation, recurrence risk) in order to identify the most appropriate drug for treatment.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited